EUVIMEDEUVIMED entdecken
Crossref

Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma

Abiola Bolarinwa iD, Saurabh Zanwar iD, Nadine Abdallah iD, Francis K Buadi, Suzanne R Hayman, Morie A Gertz iD, Angela Dispenzieri iD, Eli Muchtar iD, Prashant Kapoor, Wilson Gonsalves iD, Taxiarchis Kourelis iD, David Dingli iD und 12 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.70099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Abiola Bolarinwa und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunoglobulin Light Chains. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Light chain multiple myeloma (LCMM) is a subtype of multiple myeloma (MM) characterized by the exclusive production of immunoglobulin light chains and accounts for 15%–20% of newly diagnosed MM. A comprehensive comparison of LCMM with MM producing intact immunoglobulin (non‐LCMM) remains limited. In this retrospective study, we described distinct clinical and cytogenetic features and assessed long‐term outcomes in 852 LCMM patients diagnosed between 01/01/2004 and 12/31/2022, compared with non‐LCMM controls matched for age, sex, and year of diagnosis. On univariable analysis, LCMM patients were more likely to present with elevated creatinine (> 2 mg/dL), beta‐2‐microglobulin ≥ 5.5 mg/L, elevated LDH, hypercalcemia, t(11;14), del(13q), and t(6;14). Conversely, IMS‐IMWG high‐risk disease, hyperdiploidy, t(4;14), and serum albumin < 3.5 g/dL were less common. On multivariable analysis, elevated creatinine (OR: 5.1, 95% CI: 1.2–27, p = 0.04), t(11;14) (OR: 2.6, 95% CI: 1.3–5.2, p = 0.006), and del(13q) (OR: 4.1, 95% CI: 2.1–8.2, p < 0.001) were independently associated with LCMM, while IMS‐IMWG high‐risk disease (OR: 0.3, 95% CI: 0.1–0.8, p = 0.02) and hyperdiploidy (OR: 0.3, 95% CI: 0.1–0.7, p = 0.002) were less frequent. Despite these differences, progression‐free survival with frontline treatment (HR: 0.97, 95% CI: 0.84–1.11, p = 0.63) and overall survival (HR: 0.99, 95% CI: 0.87–1.13, p = 0.94) were similar between LCMM and non‐LCMM patients. This study highlights the distinct clinical and cytogenetic features of LCMM, marked by higher rates of renal failure, t(11;14), and del(13q), lower prevalence of IMS‐IMWG high‐risk disease, and comparable survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunoglobulin Light ChainsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAged, 80 and overAdultTreatment OutcomeDisease-Free Survival

Stichwörter der Autor:innen

IMS/IMWG high riskcast nephropathylight chain multiple myelomaoverall survivalprogression free survivalt(11;14)

Substanzen

Immunoglobulin Light Chains

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Abiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, Morie A Gertz, Angela Dispenzieri, Eli Muchtar, Wilson Gonsalves, Taxiarchis Kourelis, David Dingli, Rahma Warsame, Nelson Leung, Joselle Cook, Moritz Binder, Yi Hwa, Dragan Jevremovic, S Vincent Rajkumar, Shaji K Kumar

Zitieren

APA

Bolarinwa, A., Zanwar, S., Abdallah, N., Buadi, F. K., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Muchtar, E., Kapoor, P., Gonsalves, W., Kourelis, T., Dingli, D., Warsame, R., Leung, N., Cook, J., Binder, M., Lin, Y., Hwa, Y., Rogers, M. G., …, & Kumar, S. K. (2025). Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma. American Journal of Hematology. https://doi.org/10.1002/ajh.70099

Vancouver

Bolarinwa A, Zanwar S, Abdallah N, Buadi FK, Hayman SR, Gertz MA, et al. Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma. American Journal of Hematology. 2025. doi:10.1002/ajh.70099

BibTeX
@article{Bolarinwa2025,
  author = {Bolarinwa, Abiola and Zanwar, Saurabh and Abdallah, Nadine and Buadi, Francis K and Hayman, Suzanne R and Gertz, Morie A and Dispenzieri, Angela and Muchtar, Eli and Kapoor, Prashant and Gonsalves, Wilson and Kourelis, Taxiarchis and Dingli, David and Warsame, Rahma and Leung, Nelson and Cook, Joselle and Binder, Moritz and Lin, Yi and Hwa, Yi and Rogers, Michelle G and Hobbs, Miriam and Fonder, Amie and Jevremovic, Dragan and Rajkumar, S Vincent and Kumar, Shaji K},
  title = {Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.70099}
}
Kostenlos starten →